PL339381A1 - Antagonists of vitronectin receptor - Google Patents
Antagonists of vitronectin receptorInfo
- Publication number
- PL339381A1 PL339381A1 PL98339381A PL33938198A PL339381A1 PL 339381 A1 PL339381 A1 PL 339381A1 PL 98339381 A PL98339381 A PL 98339381A PL 33938198 A PL33938198 A PL 33938198A PL 339381 A1 PL339381 A1 PL 339381A1
- Authority
- PL
- Poland
- Prior art keywords
- antagonists
- vitronectin receptor
- vitronectin
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/14—[b,f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5934297P | 1997-09-19 | 1997-09-19 | |
US6343897P | 1997-10-29 | 1997-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL339381A1 true PL339381A1 (en) | 2000-12-18 |
Family
ID=26738652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL98339381A PL339381A1 (en) | 1997-09-19 | 1998-09-18 | Antagonists of vitronectin receptor |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP1025090A4 (en) |
JP (1) | JP2001517658A (en) |
KR (1) | KR20010024141A (en) |
CN (1) | CN1278250A (en) |
AP (1) | AP2000001766A0 (en) |
AR (1) | AR015446A1 (en) |
AU (1) | AU738433B2 (en) |
BG (1) | BG104314A (en) |
BR (1) | BR9812340A (en) |
CA (1) | CA2303487A1 (en) |
CO (1) | CO5011087A1 (en) |
DZ (1) | DZ2609A1 (en) |
EA (1) | EA200000336A1 (en) |
HU (1) | HUP0003641A3 (en) |
ID (1) | ID24162A (en) |
IL (1) | IL135028A0 (en) |
MA (1) | MA26547A1 (en) |
NO (1) | NO20001407D0 (en) |
NZ (1) | NZ503389A (en) |
OA (1) | OA11341A (en) |
PE (1) | PE122699A1 (en) |
PL (1) | PL339381A1 (en) |
SK (1) | SK4082000A3 (en) |
TR (1) | TR200000721T2 (en) |
TW (1) | TW513303B (en) |
WO (1) | WO1999015508A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO4920232A1 (en) * | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | DIBENZO [A, D] CYCLLOHEPTANE ACETIC ACIDS WITH VITRONECTIN RECEPTOR ANTAGONIST ACTIVITY |
AU747503B2 (en) | 1999-02-03 | 2002-05-16 | Merck & Co., Inc. | Benzazepine derivatives as alpha-V integrin receptor antagonists |
DE19936780A1 (en) | 1999-08-09 | 2001-02-15 | Basf Ag | New integrin receptor antagonists |
US6881736B1 (en) | 1999-09-07 | 2005-04-19 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
EG24179A (en) * | 1999-09-07 | 2008-09-28 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
FR2806082B1 (en) * | 2000-03-07 | 2002-05-17 | Adir | NOVEL BICYCLIC ANTAGONIST VITRONECTIN RECEPTOR COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
AU2001268490A1 (en) | 2000-06-15 | 2001-12-24 | Pharmacia Corporation | Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists |
JP2004513953A (en) * | 2000-10-24 | 2004-05-13 | メルク エンド カムパニー インコーポレーテッド | Dibenzoxazepine αV integrin receptor antagonist |
RU2316337C2 (en) | 2001-04-24 | 2008-02-10 | Мерк Патент Гмбх | Combined therapy by using antiangiogenic agents and tnf-alpha |
GB0215867D0 (en) * | 2002-07-09 | 2002-08-14 | Glaxosmithkline Spa | Novel method and compounds |
US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
ES2521679T3 (en) | 2006-01-18 | 2014-11-13 | Merck Patent Gmbh | Specific therapy using integrin ligands for cancer treatment |
MX2009007597A (en) | 2007-01-18 | 2009-07-22 | Merck Patent Gmbh | Specific therapy and medicament using integrin ligands for treating cancer. |
EA201101651A1 (en) | 2009-05-25 | 2012-08-30 | Мерк Патент Гмбх | CONTINUOUS INTRODUCTION OF INTEGRINE LIGANDS FOR CANCER TREATMENT |
CN106572997A (en) | 2014-05-30 | 2017-04-19 | 辉瑞公司 | Carbonitrile derivatives as selective androgen receptor modulators |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH443281A (en) * | 1964-02-18 | 1967-09-15 | Hoffmann La Roche | Process for the preparation of dibenzocycloheptatriene compounds |
US3335148A (en) * | 1966-02-17 | 1967-08-08 | Lilly Co Eli | 9(3-pyridyl)derivative of fluorene, 9-fluorenol, xanthene, 9-xanthenol and the corresponding nonphytotoxic acid addition salts thereof |
US5698551A (en) * | 1995-04-07 | 1997-12-16 | Novo Nordisk A/S | Heterocyclic compounds |
ATE238996T1 (en) * | 1995-06-29 | 2003-05-15 | Smithkline Beecham Corp | INTEGRIN RECEPTOR ANTAGONISTS |
US5659033A (en) * | 1995-09-13 | 1997-08-19 | Neurogen Corporation | N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands |
JP2001501951A (en) * | 1996-10-07 | 2001-02-13 | スミスクライン・ビーチャム・コーポレイション | How to stimulate bone formation |
CO4920232A1 (en) * | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | DIBENZO [A, D] CYCLLOHEPTANE ACETIC ACIDS WITH VITRONECTIN RECEPTOR ANTAGONIST ACTIVITY |
-
1998
- 1998-09-16 PE PE1998000881A patent/PE122699A1/en not_active Application Discontinuation
- 1998-09-16 AR ARP980104604A patent/AR015446A1/en not_active Application Discontinuation
- 1998-09-16 DZ DZ980219A patent/DZ2609A1/en active
- 1998-09-18 EA EA200000336A patent/EA200000336A1/en unknown
- 1998-09-18 WO PCT/US1998/019466 patent/WO1999015508A1/en not_active Application Discontinuation
- 1998-09-18 JP JP2000512816A patent/JP2001517658A/en not_active Withdrawn
- 1998-09-18 CO CO98053986A patent/CO5011087A1/en unknown
- 1998-09-18 PL PL98339381A patent/PL339381A1/en unknown
- 1998-09-18 MA MA25266A patent/MA26547A1/en unknown
- 1998-09-18 NZ NZ503389A patent/NZ503389A/en not_active IP Right Cessation
- 1998-09-18 AP APAP/P/2000/001766A patent/AP2000001766A0/en unknown
- 1998-09-18 HU HU0003641A patent/HUP0003641A3/en unknown
- 1998-09-18 ID IDW20000468A patent/ID24162A/en unknown
- 1998-09-18 KR KR1020007002901A patent/KR20010024141A/en not_active Application Discontinuation
- 1998-09-18 CN CN98810811A patent/CN1278250A/en active Pending
- 1998-09-18 BR BR9812340-8A patent/BR9812340A/en not_active Application Discontinuation
- 1998-09-18 EP EP98947116A patent/EP1025090A4/en not_active Withdrawn
- 1998-09-18 TR TR2000/00721T patent/TR200000721T2/en unknown
- 1998-09-18 AU AU93972/98A patent/AU738433B2/en not_active Ceased
- 1998-09-18 SK SK408-2000A patent/SK4082000A3/en unknown
- 1998-09-18 CA CA002303487A patent/CA2303487A1/en not_active Abandoned
- 1998-09-18 IL IL13502898A patent/IL135028A0/en unknown
- 1998-09-23 TW TW087115535A patent/TW513303B/en not_active IP Right Cessation
-
2000
- 2000-03-16 OA OA1200000079A patent/OA11341A/en unknown
- 2000-03-17 NO NO20001407A patent/NO20001407D0/en not_active Application Discontinuation
- 2000-04-07 BG BG104314A patent/BG104314A/en unknown
Also Published As
Publication number | Publication date |
---|---|
DZ2609A1 (en) | 2003-03-01 |
AU738433B2 (en) | 2001-09-20 |
CN1278250A (en) | 2000-12-27 |
ID24162A (en) | 2000-07-13 |
TW513303B (en) | 2002-12-11 |
TR200000721T2 (en) | 2000-11-21 |
OA11341A (en) | 2003-12-10 |
AU9397298A (en) | 1999-04-12 |
WO1999015508A1 (en) | 1999-04-01 |
AR015446A1 (en) | 2001-05-02 |
MA26547A1 (en) | 2004-12-20 |
NZ503389A (en) | 2002-03-28 |
NO20001407L (en) | 2000-03-17 |
BG104314A (en) | 2001-01-31 |
EP1025090A4 (en) | 2000-11-08 |
SK4082000A3 (en) | 2000-09-12 |
NO20001407D0 (en) | 2000-03-17 |
JP2001517658A (en) | 2001-10-09 |
KR20010024141A (en) | 2001-03-26 |
AP2000001766A0 (en) | 1998-09-18 |
BR9812340A (en) | 2001-12-18 |
CO5011087A1 (en) | 2001-02-28 |
EA200000336A1 (en) | 2000-10-30 |
CA2303487A1 (en) | 1999-04-01 |
PE122699A1 (en) | 2000-02-12 |
EP1025090A1 (en) | 2000-08-09 |
IL135028A0 (en) | 2001-05-20 |
HUP0003641A3 (en) | 2002-10-28 |
HUP0003641A2 (en) | 2001-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL327626A1 (en) | Antagonists of vitronectin receptor | |
PL327694A1 (en) | Antagonists of vitronectin receptor | |
CY2576B1 (en) | Vitronectin receptor antagonists | |
PL334499A1 (en) | Antagonists of vitronectin receptors | |
EP1000031A4 (en) | Vitronectin receptor antagonist | |
IL125034A0 (en) | Vitronectin receptor antagonists | |
EP0767792A4 (en) | Vitronectin receptor antagonists | |
ZA955391B (en) | Vitronectin receptor antagonists | |
PL339134A1 (en) | Antagonists of il-8 receptor | |
PL334756A1 (en) | Antagonists of il-8 receptor | |
PL339381A1 (en) | Antagonists of vitronectin receptor | |
IL135189A0 (en) | Vitronectin receptor antagonist | |
IL138245A0 (en) | Vitronectin receptor antagonists | |
IL135188A0 (en) | Vitronectin receptor antagonist | |
PL334774A1 (en) | Antagonists of il-8 receptor | |
PL339133A1 (en) | Antagonists of il-8 receptor | |
IL141163A0 (en) | Vitronectin receptor antagonists | |
ZA988562B (en) | Vitronectin receptor antagonists | |
SI0957917T1 (en) | Vitronectin receptor antagonists | |
GB9810182D0 (en) | Vitronectin receptor antagonists | |
GB9812686D0 (en) | Vitronectin receptor antagonists | |
GB9807384D0 (en) | Vitronectin receptor antagonists | |
GB9810882D0 (en) | Vitronectin receptor antagonists | |
GB9810892D0 (en) | Vitronectin receptor antagonists | |
GB9811295D0 (en) | Vitronectin receptor antagonists |